A Randomised, Double-Blind, Dose Ranging Clinical Trial of Intravenous FDY-5301 in Acute STEMI Patients Undergoing Primary PCI: The CAMPFIRE (CArdiac Muscle Preservation Following Ischemia REperfusion) Study

David Adlam(University College London), CCC-ACS Investigators, Joseph B. Selvanayagam(Flinders Medical Centre), János Tomcsányi, Azfar Zaman(Royal Stoke University Hospital), Simon Tulloch(Faraday Technology (United States)), Gergely Nagy(Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház), Cheerag Shirodaria(Oxford University Hospitals NHS Trust), István Édes(University of Debrecen), Lewis Siegel, Joanna Szachniewicz, Keith G. Oldroyd(Biosensores (Spain)), N. Uren, Paweł Ptaszyński(Medical University of Lodz), Piotr Musiałek(Jagiellonian University), Shahzad Munir(New Cross Hospital), Andrew Sharp(University Hospital of Wales), Hussain Contractor(National Health Service), Keith M. Channon(University of Oxford), M. J Garcia, Róbert Gábor Kiss
Circulation
December 17, 2019
Cited by 1

Related Papers

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data
|The Lancet|2018|1.1k
Preeclampsia and Future Cardiovascular Health
|Circulation Cardiovascular Quality and Outcomes|2017|1.1k
Randomized Trial of Preventive Angioplasty in Myocardial Infarction
|New England Journal of Medicine|2013|1k
Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
|The Lancet|2017|1k